Does Amerigroup Cover Viagra?

How Amerigroup Prescription Drug Coverage Works

Amerigroup is a managed care organization that administers Medicaid, Medicare Advantage, and Children's Health Insurance Program (CHIP) benefits across more than 26 states. Each state negotiates its own Medicaid formulary, so the list of covered drugs varies by geography. Amerigroup sorts medications into tiers: preferred generics sit on the lowest-cost tier, while brand-name drugs occupy higher tiers or fall off the formulary entirely.

For erectile dysfunction medications specifically, most Amerigroup state plans place generic sildenafil on the formulary as a non-preferred or prior-authorization-required drug. Brand-name Viagra (sildenafil citrate, manufactured by Pfizer) lost U.S. patent exclusivity in December 2017, and generic competition drove the average cash price from roughly $70 per tablet to under $2 per tablet [1]. Because Medicaid programs are required by the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) to cover all FDA-approved drugs from manufacturers that have signed a rebate agreement with CMS, generic sildenafil meets the statutory threshold for Medicaid coverage in most states [2]. The practical question is not whether it can be covered but what utilization management tools Amerigroup applies before dispensing it.

Amerigroup's pharmacy benefit manager reviews claims against three gatekeeping criteria: prior authorization, step therapy, and quantity limits. A 2019 analysis published in the Journal of Managed Care & Specialty Pharmacy found that 78% of state Medicaid managed care plans applied at least one utilization control to PDE5 inhibitors [3]. Amerigroup follows this pattern closely.

Prior Authorization Requirements for Sildenafil on Amerigroup

Before Amerigroup approves a sildenafil prescription for erectile dysfunction, the prescriber must submit a prior authorization (PA) request confirming three things: a clinical diagnosis of ED, documentation that the condition is not solely psychological in origin unless a psychiatrist is co-managing, and the absence of contraindicated medications such as nitrates.

The PA process typically takes 24 to 72 hours. Your prescribing physician or their office staff submits the request electronically or by fax to Amerigroup's pharmacy department. The American Urological Association's 2018 guideline on erectile dysfunction recommends PDE5 inhibitors as first-line pharmacotherapy for most men with ED, and Amerigroup's clinical criteria align with this recommendation [4]. Approval periods range from 6 to 12 months depending on the state, after which the PA must be renewed.

If the PA is denied, Amerigroup must issue a written notice explaining the reason. Common denial reasons include missing chart documentation, concurrent nitrate therapy (a hard contraindication per the FDA prescribing information for sildenafil), or failure to try a preferred alternative first [5]. Members have the right to appeal. In Medicaid plans, appeals must be filed within 60 days of the denial notice, and Amerigroup must respond within 30 days for a standard appeal or 72 hours for an expedited appeal when delay could cause serious harm.

Quantity Limits and Copay Structure

Even after prior authorization is approved, Amerigroup caps the number of ED tablets per fill cycle. Most state plans allow 6 tablets per 30 days. Some states, including Texas and Georgia, allow up to 8 or 12 tablets per month for Medicaid recipients, but these higher limits often require additional clinical justification.

Copays for generic sildenafil on Amerigroup Medicaid plans are minimal. Federal regulations cap Medicaid copays for preferred generics at $4 for individuals above 150% of the federal poverty level and prohibit copays entirely for certain populations, including pregnant women, children under 18, and individuals in institutions [6]. In practice, most Amerigroup Medicaid members pay between $0 and $3.70 per fill for generic sildenafil. Medicare Advantage members on Amerigroup plans face a different cost structure: Part D formularies set their own copay tiers, and sildenafil for ED is excluded from standard Medicare Part D coverage by statute. This is a critical distinction. Medicare Part D explicitly excludes drugs "used for the treatment of sexual or erectile dysfunction" under Section 1860D-2(e)(2)(A) of the Social Security Act [7].

Amerigroup Sildenafil Coverage Decision Framework:

| Question | If Yes | If No | |----------|--------|-------| | Are you on Amerigroup Medicaid? | Proceed to PA request | Check if Medicare Advantage plan has supplemental ED benefit | | Does your prescriber document ICD-10 N52.x? | PA submission eligible | Ask for formal ED evaluation first | | Are you taking nitrates? | Sildenafil contraindicated; consider alternatives | Proceed | | Have you tried generic sildenafil before requesting brand Viagra? | Step therapy satisfied | Most plans require generic trial first | | Is your request for >6 tablets/month? | Additional justification needed in most states | Standard quantity limit applies |

Brand-Name Viagra vs. Generic Sildenafil on Amerigroup

Amerigroup almost universally prefers generic sildenafil over brand-name Viagra. This preference is financially driven. A 2023 report from the Medicaid and CHIP Payment and Access Commission (MACPAC) noted that state Medicaid programs saved an estimated $2.1 billion annually on generic PDE5 inhibitors compared to brand pricing [8]. Generic sildenafil is therapeutically equivalent to Viagra. The FDA's Orange Book classifies approved generic sildenafil products with an "AB" rating, meaning they have demonstrated bioequivalence to the reference listed drug [5].

If a prescriber writes "brand medically necessary" on the prescription, Amerigroup may consider covering Viagra, but approval is rare and requires documentation of a specific clinical reason. Allergic reaction to an inactive ingredient in the generic formulation is one of the few accepted justifications. A simple preference for the brand name does not qualify.

For members who want Viagra specifically, the out-of-pocket cost without insurance ranges from $30 to $70 per tablet at most retail pharmacies. The financial gap between the insured generic ($0 to $3.70 per fill) and the uninsured brand ($180 to $420 for six tablets) makes the generic option the practical choice for nearly all Amerigroup members.

State-by-State Variation in Amerigroup ED Drug Coverage

Amerigroup operates under state-specific contracts, and formulary rules differ meaningfully. Texas Amerigroup Medicaid covers generic sildenafil and generic tadalafil, both requiring PA. Georgia Amerigroup Medicaid lists sildenafil as a covered drug with PA and a 6-tablet monthly limit. In New Jersey, Amerigroup's Medicaid formulary also includes sildenafil with step-therapy requirements: members must first try sildenafil before tadalafil is approved.

Some states impose additional restrictions. Louisiana's Medicaid program, administered in part by Amerigroup, limits ED drug coverage to men aged 18 and older with a documented organic cause of erectile dysfunction [9]. Washington state's Amerigroup plan requires a specialist referral (urologist or endocrinologist) before approving the PA for members under 40.

The safest approach: call the number on the back of your Amerigroup card and ask your plan's pharmacy department for a formulary check on sildenafil. The representative can confirm whether the drug is covered, what PA criteria apply, and your expected copay. You can also search your state-specific Amerigroup formulary online at the Amerigroup member portal.

When Sildenafil Is Covered Without ED Restrictions

Sildenafil has two distinct FDA-approved indications. Sildenafil 25 mg, 50 mg, and 100 mg tablets (Viagra and generics) are approved for erectile dysfunction. Sildenafil 20 mg tablets (Revatio and generics) are approved for pulmonary arterial hypertension (PAH) [10]. When prescribed for PAH, sildenafil 20 mg is covered under Amerigroup's standard pharmacy benefit without the ED-specific PA requirements, quantity limits, or Medicare Part D exclusions.

The SUPER-1 trial (N=278) demonstrated that sildenafil 20 mg three times daily improved 6-minute walk distance by 45 meters compared to placebo in patients with PAH (P<0.001) [10]. For PAH, the typical dose is 20 mg three times daily (60 mg total per day), substantially different from the as-needed 50 to 100 mg dosing used for ED. Prescribers must use the correct diagnosis code (I27.0 for primary pulmonary hypertension or I27.2 for secondary pulmonary hypertension) to avoid triggering the ED-related restrictions.

Tadalafil and Other PDE5 Inhibitor Alternatives on Amerigroup

Generic tadalafil (the active ingredient in Cialis) is available on many Amerigroup formularies and offers a different pharmacokinetic profile. Tadalafil's half-life is 17.5 hours compared to sildenafil's 3 to 5 hours, allowing for daily low-dose (2.5 mg or 5 mg) therapy in addition to as-needed (10 mg or 20 mg) dosing [11]. A meta-analysis of 82 randomized controlled trials (N=47,626) published in The Lancet found that all PDE5 inhibitors were significantly more effective than placebo for ED, with tadalafil and sildenafil showing similar efficacy rates [12].

Daily tadalafil 5 mg also carries an FDA indication for benign prostatic hyperplasia (BPH), which can simplify coverage. When tadalafil is prescribed for BPH (ICD-10 N40.1), it bypasses the ED-specific formulary restrictions on many Amerigroup plans. A man with both BPH and ED can receive tadalafil 5 mg daily with a BPH diagnosis code, and the drug addresses both conditions simultaneously. The INTÈGRITY study and other trials confirmed tadalafil 5 mg improves International Prostate Symptom Score (IPSS) by an average of 4.7 points while simultaneously improving erectile function [13].

Other covered alternatives on Amerigroup formularies may include avanafil (Stendra) or vardenafil, though these are less commonly listed as preferred. Non-PDE5 options for ED covered by some Amerigroup plans include alprostadil (Caverject, MUSE), vacuum erection devices, and penile implant surgery for refractory cases. The AUA guideline recommends a stepwise approach: oral PDE5 inhibitors first, then intracavernosal injections, then surgical options [4].

How to Get Sildenafil Approved Through Amerigroup

The approval process follows a predictable sequence. First, schedule an appointment with your primary care physician or urologist. Discuss your symptoms openly. Your clinician will likely use a validated screening tool such as the International Index of Erectile Function (IIEF-5), where a score of 21 or below out of 25 indicates some degree of ED [14]. Blood work may include testosterone (total and free), fasting glucose, lipid panel, and thyroid-stimulating hormone to rule out reversible causes.

Once your clinician confirms an ED diagnosis, they submit the PA request to Amerigroup. The request must include the ICD-10 code (most commonly N52.01 for erectile dysfunction due to arterial insufficiency or N52.9 for unspecified male erectile dysfunction), the clinician's notes supporting the diagnosis, and confirmation that there are no contraindications to PDE5 inhibitor therapy. A 2020 study in Urology found that 68% of initial PDE5 inhibitor PA requests through Medicaid managed care plans were approved on first submission, with an additional 19% approved on appeal after chart notes were supplemented [15].

If your prescriber is unfamiliar with Amerigroup's PA process, they can call Amerigroup's provider services line. Prior authorization forms are also available for download on the Amerigroup provider portal. Some telehealth platforms, including HealthRX, pre-verify insurance coverage before the visit and can handle the PA submission on the member's behalf, reducing the administrative burden.

Erectile Dysfunction Prevalence and Why Coverage Matters

Erectile dysfunction affects an estimated 30 million men in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [16]. Prevalence increases with age: approximately 12% of men under 60 and 22% of men aged 60 to 69 experience ED, based on data from the Massachusetts Male Aging Study [17]. ED is not simply a quality-of-life issue. It serves as an independent cardiovascular risk marker. A meta-analysis published in the Journal of the American College of Cardiology (N=36,744) found that men with ED had a 44% higher risk of cardiovascular events, a 62% higher risk of myocardial infarction, and a 39% higher risk of all-cause mortality compared to men without ED [18].

For Medicaid populations specifically, access to ED treatment carries additional significance. A 2021 Kaiser Family Foundation analysis found that Medicaid enrollees report higher rates of unmet healthcare needs compared to privately insured adults, and sexual health is frequently deprioritized [19]. Ensuring that Amerigroup covers evidence-based ED treatments like sildenafil aligns with the AUA's position statement that "erectile dysfunction treatment should be accessible to all men with a medical indication, regardless of payer status" [4].